Despite finishing strong across both its innovative and generic businesses in 2024, Teva’s cautious approach to the new year ...

The Trump administration’s executive order pausing foreign aid programs has sent crash waves through relief organizations ...

Want the eyeballs of people with obesity? Think TV. That is a takeaway from a CMI survey that suggests the fight for ...

Two attempts by Johnson & Johnson to resolve approximately 60,000 talcum powder lawsuits through bankruptcy courts have ...

As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...

A squadron of senators is once again putting forward a proposal to boost price transparency in direct-to-consumer ...

The Partnership to Fight Infectious Disease has put out a timely notice about support for vaccines. Forty-five minutes before ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical ...